The effect of doxofylline in asthma and COPD.


Journal

Respiratory medicine
ISSN: 1532-3064
Titre abrégé: Respir Med
Pays: England
ID NLM: 8908438

Informations de publication

Date de publication:
04 2020
Historique:
received: 18 11 2019
accepted: 17 02 2020
pubmed: 26 2 2020
medline: 22 10 2020
entrez: 26 2 2020
Statut: ppublish

Résumé

Theophylline is still one of the most widely prescribed drugs for the treatment of asthma and COPD in developing countries because the majority of asthma and COPD medicines are largely unavailable and also because it is a cheap option. In any case, its anti-inflammatory effects and capacity to reverse corticosteroid resistance deserve consideration, but it can induce numerous side effects and drug-drug interactions and frequently requires measurement of drug levels in plasma. In order to overcome the problems posed by theophylline, other xanthines have been developed. Doxofylline is a newer generation xanthine with both bronchodilating and anti-inflammatory activities and for this reason it has been called "novofylline". It differs substantially from theophylline at the pharmacological level. Clinical studies have shown substantial differences between doxofylline and theophylline. In particular, efficacy/safety profile of doxofylline is better than that of theophylline.

Identifiants

pubmed: 32094104
pii: S0954-6111(20)30044-5
doi: 10.1016/j.rmed.2020.105904
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Bronchodilator Agents 0
Theophylline C137DTR5RG
doxofylline MPM23GMO7Z

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

105904

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interests The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: MC has participated as an advisor in scientific meetings sponsored by ABC Farmaceutici and Mundipharma Bangladesh that manufacture and sell medicinal products containing doxofylline; he is a consultant to ABC Farmaceutici. MGM has participated as an advisor in scientific meetings sponsored by ABC Farmaceutici.

Auteurs

Mario Cazzola (M)

Chair of Respiratory Medicine, Department of Experimental Medicine, University of Rome Tor Vergata, Italy. Electronic address: mario.cazzola@uniroma2.it.

Maria Gabriella Matera (MG)

Chair of Pharmacology, Department of Experimental Medicine, University of Campania, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH